Navigation Links
Heptares Therapeutics Enters Agreement With Daiichi Sankyo to Discover and Develop Novel, Small-molecules for the Treatment of Pain
Date:3/13/2017

LONDON, March 13, 2017 /PRNewswire/ --

Heptares Therapeutics ("Heptares"), a wholly owned subsidiary of Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565) announces that it has entered into a drug discovery and licensing agreement with Daiichi Sankyo Company, Limited ("Daiichi Sankyo") focused on a single G protein-coupled receptor (GPCR) nominated by Daiichi Sankyo that plays a crucial role in relieving pain.

Under the terms of the agreement, Daiichi Sankyo will receive exclusive global rights to develop, manufacture and commercialize novel, small molecules discovered by Heptares focused on the nominated GPCR. In return, Heptares will receive an upfront payment of $4 million, research funding of approximately $8 million, and is eligible to receive additional research, development and commercialization milestone payments. In addition, Heptares will be eligible to receive royalties on net sales of products resulting from the alliance.

"This is a very exciting new collaboration as relieving pain presents a significant challenge," said Malcolm Weir, Heptares CEO and Chief R&D Officer of Sosei. "We are confident that the unique structural insights of the receptor that our technologies can deliver combined with expertise on its role in pain from the Neurosciences team at Daiichi Sankyo will yield new, differentiated molecules that can be advanced into development."

Notes to Editors

About Heptares Therapeutics 

Heptares is a clinical-stage company creating transformative medicines targeting G protein-coupled receptors (GPCRs), a superfamily of 375 receptors linked to a wide range of human diseases. Heptares' proprietary StaR® technology and structure-based drug design (SBDD) capabilities enable us to engineer and develop drugs for highly validated, yet historically undruggable or challenging GPCRs. Using this approach, we are building an exciting pipeline of new medicines (small molecules and biologics) with the potential to transform the treatment of Alzheimer's disease, schizophrenia, cancer immune-oncology, migraine, addiction, metabolic disease and other indications. We have partnerships for our novel candidates and technologies with leading pharmaceutical and biotechnology companies, including Allergan, AstraZeneca, Daiichi Sankyo, Kymab, MedImmune, MorphoSys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation. For more information, please visit www.heptares.com and www.sosei.com.

HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;

StaR® is a registered trademark in the EU and Japan. 

About Sosei 

Sosei is a biopharmaceutical company originating from Japan but with global presence. Sosei's primary business model is based on identifying novel and/or differentiated product assets or technology platforms and, through supporting these in preclinical and clinical development and establishing commercial partnerships, advancing new medicines to patients worldwide. For more information about Sosei, please visit www.sosei.com.

About Daiichi Sankyo 

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group's 2025 Vision to become a "Global Pharma Innovator with a Competitive Advantage in Oncology," Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com. Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is a member of the Daiichi Sankyo Group. For more information on Daiichi Sankyo, Inc., please visit: www.dsi.com.



'/>"/>
SOURCE Heptares Therapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Heptares and Kymab Enter Strategic Collaboration to Discover, Develop and Commercialise Novel Antibody Therapeutics
2. Heptares Joins Pharma Consortium Applying State of the Art Cryo-Electron Microscopy to Advance Structure Based Drug Discovery
3. Heptares Announces Positive Results from Phase 1b Clinical Trial with HTL9936, a First-in-class Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Dementia and Schizophrenia
4. Heptares Enters Strategic Drug Discovery Collaboration with Pfizer Inc. Focused on GPCR Targets Across Multiple Therapeutic Areas
5. Heptares Awarded $5.5 Million Research & Development Grant From the US National Institute on Drug Abuse (NIDA)
6. Heptares Announces Positive Outcome of Phase 1A Study with First-ever Selective Muscarinic M1 Receptor Agonist for Improving Cognition in Patients With Alzheimers Disease
7. Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery
8. Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States
9. Heptares First-in-Class Selective Muscarinic Agonists Chosen as one of top Neuroscience Projects to Watch
10. Heptares to Present on Structure-Based Drug Design Using G Protein-Coupled Receptors at Inaugural Chemistry & Engineering News Virtual Symposium
11. Heptares to Present at CNS Partnering & Deal-making and Biopharm America
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 ... platform, the first non-viral gene expression technology that enables ... the eye to address a wide range of ophthalmic ... Medicines and Healthcare products Regulatory Agency (MHRA) to advance ... ...
(Date:4/19/2017)... April 19, 2017 Cardiology devices segment is anticipated ... The Cardiology Devices segment is likely to create ... Mn in 2018 over 2017. By the end of 2027, ... close to US$ 700 Mn, expanding at a CAGR of ... the Asia Pacific reprocessed medical devices ...
(Date:4/19/2017)... 19, 2017 Global Prostate Cancer Therapeutics ... the prostate cancer therapeutics market analyzes the current ... prevalence of prostate cancer, launch of promising emerging ... of new drugs & therapeutic biological products, and ... to lesser side effects are some of the ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, ... and which He does not. Yisrayl says with so many titles and names for ... but he says with a little Scripture, backed with a lot of research, the truth ...
(Date:4/28/2017)... ... April 28, 2017 , ... Phytomer USA is ... Côté has 20+ years of experience within the beauty industry, ranging from marketing, ... array of high-end cosmetic brands, retail brands and outlets in Canada and New ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... advanced nutraceutical supplements, through its Nova Skin Sciences division, recently announced the launch ... a moisturizer with the power of an anti-aging concentrate. , Anogeissus ...
(Date:4/28/2017)... ... ... Rob Lowe is a popular actor that has been in many different movies ... as the host of the “Informed” series. The program focuses on many important issues ... focuses on thyroid cancer. , Although thyroid cancer is an uncommon type of cancer, ...
(Date:4/28/2017)... ... ... Christie Medical Holdings, Inc. , with its market-leading vein finder ... a leader in infusion therapy and pain management. , Intravenous (IV) therapy plays ... patients receiving a peripheral IV catheter as part of their treatment plan. Many hospitals ...
Breaking Medicine News(10 mins):